CRISPR Therapeutics AG's Recent Performance and Future Prospects

CRISPR Therapeutics AG (CRSP) closed at $48.81, a 2.61% increase from the previous day. The stock has dropped 18.07% in the past month, underperforming the Medical sector's 7.29% loss and the S&P 500's 4.99% loss. Analysts expect CRSP to report earnings of -$1.15 per share and revenue of $7.32 million in its upcoming earnings disclosure. The Zacks Rank system, which assesses estimate changes and presents a viable rating system, currently ranks CRSP a #3 (Hold). The Medical - Biomedical and Genetics industry is in the bottom 39% of all industries, according to the Zacks Industry Rank.